Huawei CEO Ren Zhengfei laid out plans to bring more efficiencies to the organization. This included simplifying the reporting structure, cutting down on surplus staff, axing...Technologyread more
The bond market has entered a financial twilight zone, and at this point, there doesn't seem to be a smooth way out.Market Insiderread more
China has used both monetary and fiscal measures to lift economic activity as its trade war with the U.S. looks set to intensify in the coming months.China Economyread more
President Donald Trump said on Twitter he was postponing a scheduled meeting with Denmark's prime minister because of her lack of interest in discussing a possible sale of...World Politicsread more
"I think (rate cuts) will help, but whether they're going to be sufficient to counter the negative trade pressures and global growth slowdown and impact is debatable," one...Central Banksread more
Chinese overseas investment growth will likely slow or even decline in the next few years as risks around the world increase, according to new research by Moody's Investors...China Economyread more
The two countries want to smash the civil aerospace duopoly enjoyed by Airbus and Boeing.Aerospace & Defenseread more
Alibaba held a board meeting before its latest quarterly earnings release last week, during which the board decided to postpone the Hong Kong listing, Reuters reported.Technologyread more
Federal Reserve Chairman Jerome Powell is set to deliver his annual speech on Friday at the Jackson Hole, Wyoming symposium, where he's expected to provide more clarity on the...Asia Marketsread more
U.S. and Asian investors poured $3.7 billion into U.K. tech start-ups in the first seven months of 2019, research shows.Technologyread more
After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
ZURICH, July 29 (Reuters) - Novartis said on Monday a trial for a new use of its Entresto heart drug had failed - calling into questions billions of dollars in hoped for revenue.
The drug, which is already approved for reduced fraction heart failure, narrowly missed its objectives when trialled on patients with preserved ejection fraction heart disease, which affects 13 million people globally.
"The trial narrowly missed statistical significance for its composite primary endpoint of reducing cardiovascular death and total heart failure hospitalizations," Novartis said.
Novartis said it would present the result of the trial at the European Society of Cardiology in September, and discuss next steps with clinical experts and regulators.
The company's shares fell 1.7% to 90.6 Swiss francs in early trading in Zurich following the news.
Analyst Michael Nawrath at Zuercher Kantonalbank said the likelihood of a positive outcome in the study had been low.
"The milder the disease, the higher the hurdle," he said. "It would have been very good for the momentum of Novartis, whose shares would have passed the 100 franc per share mark, on a positive outcome.
"Despite the relatively low expectations, we are talking about a negative but not sustained price reaction." (Reporting by John Revill; Editing by Kirsten Donovan)